Thomas Eisenhaure

Thomas Eisenhaure

Auto-generated profile, based on publicly available information

Thomas Eisenhaure

Broad Institute of MIT and Harvard

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2019 in Nature Immunology
Verified
Journal Article
Open access
PDF file
TNthe Accelerating Medicines Partnership in SLE network
the Accelerating Medicines Partnership in SLE network
AAArnon Arazi
Arnon Arazi
DRDeepak A. Rao
Deepak A. Rao
CBCeline C. Berthier
Celine C. Berthier
ADAnne Davidson
Anne Davidson
BDBetty Diamond
Betty Diamond
Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed kidney samples from patients with lupus nephritis and from healthy control subjects using single-cell RNA sequencing. Our analysis revealed 21 subsets of leukocytes active in disease, including multiple populations of myeloid cells, T cells, natural killer cells and B cells that demonstrated both pro-inflammatory responses and inflammation-resolving responses. We found evidence of local activation of B cells correlated with an age-associated B-cell signature and evidence of progressive stages of monocyte differentiation within the kidney. A clear interferon response was observed in most cells. Two chemokine receptors, CXCR4 and CX3CR1, were broadly expressed, implying a potentially central role in cell trafficking. Gene expression of immune cells in urine and kidney was highly correlated, which would suggest that urine might serve as a surrogate for kidney biopsies.

26 July 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
PTPierre TONNERRE
Pierre TONNERRE
DWDavid Wolski
David Wolski
SSSonu Subudhi
Sonu Subudhi
JAJihad Aljabban
Jihad Aljabban
RHRuben C. Hoogeveen
Ruben C. Hoogeveen
GLGeorg M. Lauer
Georg M. Lauer

18 December 2018 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
KMKathleen M. Mahoney
Kathleen M. Mahoney
SSSachet A. Shukla
Sachet A. Shukla
NPNikolaos Patsoukis
Nikolaos Patsoukis
ACApoorvi Chaudhri
Apoorvi Chaudhri
EBEdward P. Browne
Edward P. Browne
GFGordon J. Freeman
Gordon J. Freeman
Targeting immune checkpoint pathways, such as programmed death ligand-1 (PD-L1, also known as CD274 or B7-H1) or its receptor programmed cell death-1 (PD-1) has shown improved survival for patients with numerous types of cancers, not limited to lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma. PD-L1 is a co-inhibitory molecule whose expression on the surface of tumor cells is associated with worse prognosis in many tumors. Here we describe a splice variant (secPD-L1) that does not splice into the transmembrane domain, but instead produces a secreted form of PD-L1 that has a unique 18 amino acid tail containing a cysteine that allows it to homodimerize and more effectively inhibit lymphocyte function than monomeric soluble PD-L1. We show that recombinant secPD-L1 can dimerize and inhibit T-cell proliferation and IFN-gamma production in vitro. The secPD-L1 variant is expressed by malignant cells in vitro that also express high levels of full-length PD-L1. Transcriptomic analysis of gene expression across The Cancer Genome Atlas found the strongest association of secPD-L1 with full-length PD-L1, but also with subsets of immunologic genes, such as in myeloid-derived suppressor cells. Moreover, the splice variant is also expressed in normal tissues and within normal peripheral blood cells it is preferentially expressed in activated myeloid cells. This is the first report of a form of secreted PD-L1 that homodimerizes and is functionally active. SecPD-L1 may function as a paracrine negative immune regulator within the tumor, since secPD-L1 does not require a cell-to-cell interaction to mediate its inhibitory effect.

1 November 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
IMIlaria Marigo
Ilaria Marigo
RTRosalinda Trovato
Rosalinda Trovato
FHFrancesca Hofer
Francesca Hofer
VIVincenzo Ingangi
Vincenzo Ingangi
GDGiacomo Desantis
Giacomo Desantis
VBVincenzo Bronte
Vincenzo Bronte
Tumor-associated macrophages (TAM) are regulators of extracellular matrix (ECM) remodeling and metastatic progression, the main cause of cancer-associated death. We found that disabled homolog 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed in tumor-infiltrating TAMs and that its genetic ablation significantly impairs lung metastasis formation. DAB2-expressing TAMs, mainly localized along the tumor-invasive front, participate in integrin recycling, ECM remodeling, and directional migration in a tridimensional matrix. DAB2+ macrophages escort the invasive dissemination of cancer cells by a mechanosensing pathway requiring the transcription factor YAP. In human lobular breast and gastric carcinomas, DAB2+ TAMs correlated with a poor clinical outcome, identifying DAB2 as potential prognostic biomarker for stratification of patients with cancer. DAB2 is therefore central for the prometastatic activity of TAMs.Significance: DAB2 expression in macrophages is essential for metastasis formation but not primary tumor growth. Mechanosensing cues, activating the complex YAP–TAZ, regulate DAB2 in macrophages, which in turn controls integrin recycling and ECM remodeling in 3-D tissue matrix. The presence of DAB2+ TAMs in patients with cancer correlates with worse prognosis.This article is highlighted in the In This Issue feature, p. 1611

3 March 2020 in eLife
Verified
Journal Article
Open access
EHEmma Hajaj
Emma Hajaj
GEGalit Eisenberg
Galit Eisenberg
SKShiri Klein
Shiri Klein
SFShoshana Frankenburg
Shoshana Frankenburg
SMSharon Merims
Sharon Merims
MLMichal Lotem
Michal Lotem
SLAMF6 is a homotypic receptor of the Ig-superfamily whose exact role in immune modulation has remained elusive. Its constitutive expression on resting and activated T cells precludes it from being abona fideexhaustion marker. By breeding Pmel-1 mice with SLAMF6 -/- mice, we generated donors for T cells lacking SLAMF6 and expressing a transgenic TCR for gp100-melanoma antigen. Activated Pmel-1xSLAMF6 -/- CD8+ T cells displayed improved polyfunctionality and strong tumor cytolysis. T-bet was the dominant transcription factor in Pmel-1 x SLAMF6 -/- cells, and upon activation, they acquired an effector-memory phenotype. Adoptive transfer of Pmel-1 x SLAMF6 -/- T cells to melanoma-bearing mice resulted in lasting tumor regression in contrast to temporary responses achieved with Pmel-1 T cells. LAG-3 expression was elevated in the SLAMF6 -/- cells, and the addition of the LAG-3-blocking antibody to the adoptive transfer protocol improved the SLAMF6 -/- T cells and expedited the antitumor response even further. The results from this study support the notion that SLAMF6 is an inhibitory immune receptor whose absence enables powerful CD8+ T cells to eradicate tumors.

3 September 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
PHPaul J. Hoover
Paul J. Hoover
CRChirag Raparia
Chirag Raparia
DLDavid J. Lieb
David J. Lieb
YTYochay Tzur
Yochay Tzur
JKJoyce Kang
Joyce Kang
ADAnne Davidson
Anne Davidson
Monocytes and macrophages in patients with lupus nephritis exhibit altered behavior compared with healthy kidneys. How to optimally use mouse models to develop treatments targeting these cells is poorly understood. This study compared intrarenal myeloid cells in four mouse models and 155 lupus nephritis patients using single-cell profiling, spatial transcriptomics, and functional studies. Across mouse models, monocyte and macrophage subsets consistently expanded or contracted in disease. A subset of murine classical monocytes expanded in disease; these cells expressed Cd9, Spp1, Ctsd, Cd63, Apoe, and Trem2, genes associated with tissue injury in other organs that play roles in inflammation, lipid metabolism, and tissue repair. Resident macrophages expressed similar genes in clinical disease. In humans, we identified analogous disease-associated monocytes and macrophages that were associated with kidney histological subtypes and disease progression, sharing gene expression and localizing to similar kidney microenvironments as in mice. This cross-species analysis supports the use of mouse functional studies for understanding human lupus nephritis.